My Portfolio
+
LINK YOUR PORTFOLIO

Helus Pharma HELP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:21 PM EDT
4.31quote price arrow up+0.01 (+0.23%)
Volume
8,966
Close
4.30quote price arrow down-0.25 (-5.49%)
Volume
507,068
52 week range
4.15 - 9.83
Loading...
  • Open4.57
  • Day High4.57
  • Day Low4.30
  • Prev Close4.55
  • 52 Week High9.83
  • 52 Week High Date07/01/25
  • 52 Week Low4.15
  • 52 Week Low Date05/19/26

Latest On Helus Pharma

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.66M
  • Dividend-
  • Dividend Yield-
  • Beta-

Latest On Helus Pharma

KEY STATS

  • Open4.57
  • Day High4.57
  • Day Low4.30
  • Prev Close4.55
  • 52 Week High9.83
  • 52 Week High Date07/01/25
  • 52 Week Low4.15
  • 52 Week Low Date05/19/26
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.66M
  • Dividend-
  • Dividend Yield-
  • Beta-

RATIOS/PROFITABILITY

  • EPS (TTM)-3.61
  • P/E (TTM)-1.19
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date06/29/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and...
Eric So
Executive Chairman of the Board, Interim Chief Executive Officer
Aaron Bartlone
Chief Operating Officer
Greg Cavers
Chief Financial Officer
Address
5600-100 King St West
Toronto, ON
M5X 1C9
Canada